Lexaria Bioscience (LEXX) Selling, General & Administrative (2017 - 2026)
Lexaria Bioscience (LEXX) Selling, General & Administrative (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 582.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 662.10 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.13 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 216.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 593.21 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 347.92 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -196.26 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 247.47 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 161.89 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1.02 Mn |
| Feb 28, 2026 | 996,515.00 |
| Nov 30, 2025 | 902,291.00 |
| Aug 31, 2025 | 980,477.00 |
| May 31, 2025 | 1.21 Mn |
| Feb 28, 2025 | 1.24 Mn |
| Nov 30, 2024 | 918,690.00 |
| Aug 31, 2024 | 1.32 Mn |
| May 31, 2024 | 1.25 Mn |
| Feb 29, 2024 | 567,226.00 |
| Nov 30, 2023 | 711,107.00 |
| Aug 31, 2023 | 644,448.00 |
| May 31, 2023 | 825,177.00 |
| Feb 28, 2023 | 644,514.00 |
| Nov 30, 2022 | 947,870.00 |
| Aug 31, 2022 | 462,260.00 |
| May 31, 2022 | 1.75 Mn |
| Feb 28, 2022 | 1.20 Mn |
| Nov 30, 2021 | 1.55 Mn |
| Aug 31, 2021 | 873,584.00 |